证券代码：301290 证券简称：东星医疗 公告编号：2026-006 江苏东星智慧医疗科技股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、江苏东星智慧医疗科技股份有限公司（以下简称"公司"或"上市公司"） 于 2025 年 9 月 26 日披露《关于筹划重大资产重组暨签署<股权收购意向协议> 的提示性公告》（公告编号：2025-042），公司拟以支付现金方式购买武汉医佳 宝生物材料有限公司（以下简称"武汉医佳宝"或"标的公司"）90%的股权（以 下简称"本次交易"），本次交易如能顺利实施，武汉医佳宝将成为公司的控股 子公司。根据初步研究和测算，本次交易预计构成《上市公司重大资产重组管理 办法》规定的重大资产重组。本次交易不涉及上市公司发行股份，不构成关联交 易，也不会导致上市公司控股股东和实际控制人发生变更。 2、本次交易尚处于初步筹划阶段，交易方案和交易条款仍需进一步论证和 沟通协商，上市公司及标的公司尚需分别履行必要的内外部决策、审批程序，存 在未能通过有关决策、审批程序的风险。 本次交易中， ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 证券代码：301290 证券简称：东星医疗 公告编号：2026-005 江苏东星智慧医疗科技股份有限公司 关于持股 5%以上股东减持股份计划期限届满 暨实施情况的公告 股东江世华先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"东星医疗"或"公司"） 于 2025 年 12 月 5 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5% 以上股东减持股份的预披露公告》（公告编号：2025-055），持有公司股份 5,070,000 股（占公司总股本的 5.0612%，占剔除公司回购专户中股份总数后总股本的 5.1378%）的股东江世华先生，计划自减持计划公告披露之日起十五个交易日后 的 2 个月内（即 2025 年 12 月 29 日至 2026 年 2 月 28 日）通过集中竞价或大宗 交易方式减持公司股份不超过 986,806 股（占公司总股本比例不超过 0.9851%， 占剔除公司回购专户中股份总数后总股本比例不超过 1.0000%）。 ...

Group 1 - The company plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd. through a cash payment, which will make Wuhan Yijiaobao a subsidiary of the company if the transaction is successfully implemented [1] - The company has appointed Huatai United Securities Co., Ltd. as the independent financial advisor for this major asset restructuring [1] - Legal, evaluation, and auditing services for the restructuring will be provided by Beijing Tianyuan Law Firm, Xiamen Jiaxue Asset Appraisal Real Estate Valuation Co., Ltd., and Lixin Certified Public Accountants [1] Group 2 - The company is actively organizing due diligence, auditing, and evaluation work on the target company with various intermediary institutions [1] - Continuous communication and negotiation with relevant parties regarding the major asset restructuring are being conducted by the company [1]

江苏东星智慧医疗科技股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 江苏东星智慧医疗科技股份有限公司（以下简称"公司"或"上市公司"） 拟以支付现金方式购买武汉医佳宝生物材料有限公司（以下简称"武汉医佳宝" 或"标的公司"）90%的股权（以下简称"本次交易"），本次交易如能顺利实 施，武汉医佳宝将成为公司的控股子公司。 证券代码：301290 证券简称：东星医疗 公告编号：2026-004 2025年11月26日，公司披露了《关于筹划重大资产重组的进展公告》（公告编 号：2025-048）。 2025年12月26日，公司披露了《关于筹划重大资产重组的进展公告》（公告编 号：2025-057）。 2026年1月26日，公司披露了《关于筹划重大资产重组的进展公告》（公告编号： 2026-002）。 截至本公告披露之日，公司根据相关规定，委托华泰联合证券有限责任公司担 任本次重大资产重组的独立财务顾问，委托北京市天元律师事务所、厦门嘉学资产 评估房地产估价有限公司、立信会计师事务所（特殊普通合伙）为本次重大 ...

Group 1 - The core point of the article is that Dongxing Medical (301290) reported a total of 9,462 shareholders as of February 10, 2026, including credit accounts [1]

Group 1 - The stock price of Dongxing Medical (301290) has shown an upward trend, closing at 29.74 yuan on February 11, up approximately 3.23% from 28.81 yuan on February 5 [1] - On February 11, the stock increased by 1.78% with a trading volume of about 51.9 million yuan, although there was a net outflow of 177.20 million yuan from main funds, indicating short-term capital divergence [1] - As of February 12, the stock price slightly corrected to 29.41 yuan, down 1.11% for the day, but still up 2.08% over the past five days, outperforming the broader market [1] Group 2 - The number of shareholders in Dongxing Medical has increased, with a total of 9,302 shareholders as of January 30, reflecting a 3.44% increase, indicating heightened investor participation [2] - As of February 10, the number of shareholders continued to grow, increasing by approximately 160 accounts, or 1.72%, suggesting sustained market interest [2] - The company focuses on the anastomosis device industry chain and has not announced any other significant events recently [2]

证券日报网讯2月12日，东星医疗（301290）在互动平台回答投资者提问时表示，截至2026年2月10日， 公司股东总数为9462户(含信用账户)。 ...

Group 1 - The company, Arctech, stated that it will disclose the number of shareholders in its periodic reports [1] - As of the end of the third quarter of 2025, the total number of common stock shareholders was 48,806 [1]

Group 1 - The core point of the article is that Dongxing Medical reported a total of 9,302 shareholders as of January 30, 2026, including credit accounts [2]

Core Viewpoint - Dongxing Medical (301290.SZ) expects a net profit attributable to shareholders of the listed company to be between -45 million and -32 million yuan for 2025, indicating a challenging financial outlook due to increased market competition and a slowdown in customer demand [1] Financial Performance - The company's revenue from stapler components and medical equipment has declined, leading to a decrease in overall gross profit compared to the same period last year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -72 million and -51 million yuan for 2025 [1] Asset Impairment - Based on the prudence principle and an analysis of the operating performance and profitability of its wholly-owned subsidiary, Jiangsu Zihang Precision Hardware Co., Ltd., the company is conducting an impairment test on its asset group as of December 31, 2025 [1] - The preliminary estimate indicates that the company will recognize goodwill impairment of approximately 97.91 million yuan and intangible asset impairment of about 5.63 million yuan, totaling an impairment provision of approximately 103.54 million yuan [1] - The impact of the impairment provision on the company's net profit has been considered in the performance forecast, although the final amount will be determined after evaluation and audit by qualified assessment and auditing institutions [1]